Gilead Sciences, Inc. vs Match Group Inc — how do they compare? Gilead Sciences, Inc. trades at $135.47 (market cap $168.35B), while Match Group Inc trades at $37 (market cap $8.45B). The key difference: Gilead Sciences, Inc. is far larger — about 19.9× Match Group Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | MTCH | |
|---|---|---|
Market Cap | $168.35B | $8.45B |
Sector | Health | Media |
52-Week High | $155.80 | $41.24 |
52-Week Low | $110.56 | $28.90 |
Enterprise Value | $191.42B | $11.42B |
Dividend Yield | 2.42% | 2.17% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →